Application of laurazolette polypeptide in preparation of medicine for relieving doxorubicin cardiotoxicity

A larezole polypeptide and larezole technology are applied in the directions of drug combinations, pharmaceutical formulations, peptide/protein components, etc., to achieve the effects of preventing and treating cardiotoxicity, reducing myocardial enzyme content, and improving systolic and diastolic functions.

Pending Publication Date: 2022-08-02
李臻
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The present invention proposes for the first time to prevent and treat the cardiotoxicity induced by doxorubicin (Dox) chemotherapy by oral administration of Larazotide, which overcomes the limitations of current clinical use of Dox and the drawbacks of existing chemotherapeutic cardioprotective drugs, and simultaneously solves the problem of Dox chemotherapy. Prevention and treatment of induced cardiotoxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of laurazolette polypeptide in preparation of medicine for relieving doxorubicin cardiotoxicity
  • Application of laurazolette polypeptide in preparation of medicine for relieving doxorubicin cardiotoxicity
  • Application of laurazolette polypeptide in preparation of medicine for relieving doxorubicin cardiotoxicity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] 1. Experimental animals and grouping

[0032] SPF grade 6-8 week-old male C57BL / 6 mice, weighing about 18-20 g, were purchased from Beijing Speifu Laboratory Animal Co., Ltd. Raised in the Experimental Animal Center of Zhengzhou University.

[0033] The experimental groups included: oral PBS group (PBS group), oral PBS+injection Dox group (Dox group), oral Laazotide group (LA group), oral Laazotide+injection Dox group (LA+Dox group).

[0034] 2. Processing method

[0035] PBS group and Dox group: 1 week before the first injection of Dox, both groups were intragastrically administered 200 μl of PBS every day, and continued to be administered by intragastric administration every other day after the first Dox injection until the end of the experiment.

[0036] LA group and LA+Dox group: 1 week before the first injection of Dox, 200 μl of Larazotide was administered by gavage every day, after the first Dox injection, it was continued by gavage every other day until the en...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a larazotide in preparation of a medicine for relieving doxorubicin cardiotoxicity, and relates to a preparation method of a drug for relieving doxorubicin cardiotoxicity. In-vivo experiment results show that the Larizotide can effectively relieve the toxic effect of the chemotherapeutic drug adriamycin on the heart, and by improving the homeostasis of immune cells of the body and the heart, the cell apoptosis of myocardial tissue is relieved, the increase of myocardial zymogram is relieved, and the left ventricular diastolic ability and the cardiac ejection fraction are enhanced, so that the toxic and side effects of the chemotherapeutic drug adriamycin are reduced, and the curative effect of the chemotherapeutic drug adriamycin is improved. Meanwhile, the intestinal barrier function injury caused by adriamycin chemotherapy is also improved. The traditional Chinese medicine composition overcomes the defects of current Dox clinical medication limitation and existing chemotherapy heart protection medicines, and solves the problem of prevention and treatment of cardiotoxicity and intestinal side effects induced in Dox chemotherapy.

Description

technical field [0001] The invention relates to a new use of a larezolid polypeptide, in particular to the use of a larezolid polypeptide in a drug for relieving the cardiotoxicity of doxorubicin. Background technique [0002] Doxorubicin (Dox) is a broad-spectrum, high-efficiency anthracycline anticancer drug that is routinely used in clinical practice. It is widely used in the treatment of leukemia, malignant lymphoma, breast cancer, ovarian cancer and osteosarcoma. Although anthracyclines represented by Dox have increased the long-term survival rate of cancer patients, their dose-dependent cardiotoxicity side effects, and eventually irreversible myocardial damage and congestive heart failure, have greatly limited their use in clinical application. [0003] The current cardioprotective strategies to prevent anthracycline toxicity mainly include the use of cardioprotective agents or reducing the cumulative dose of chemotherapeutic drugs to reduce the efficacy of cardiotoxi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61P9/00A61P1/00
CPCA61K38/08A61P9/00A61P1/00
Inventor 李臻石超唐颢赵环邢珺月程晓雷简冬冬
Owner 李臻
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap